Medical Company Announces Promising Data From Phase III Parkinson's Study

Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), has announced very promising results from its Phase III study of buntanetap in patients with Parkinson’s Disease. The company's recent findings highlight significant improvements in both motor and non-motor symptoms, as well as cognitive functions among patients treated with buntanetap. $Annovis Bio(ANVS.US)$